Microalbuminuria is a condition characterized by the abnormal presence of albumin (a protein) in urine. The increased level of albumin excretion correlates with the increased risk of CKD (Chronic Kidney Disease) onset and progression (especially) in Diabetes Mellitus.
Hence, it is important that physicians have a fast, easy and reliable test to assess changes in patients.
ACT by Zensorium’s compact instrument design and dry reagent approach allows screening for kidney disease to be available in most rural area, through the enablement of true portability and increased accessibility to Patient’s Point of care.
ACT by Zensorium’s compact instrument design and dry reagent approach allows screening for kidney disease to be available in most rural area, through the enablement of true portability and increased accessibility to Patient’s Point of care.
Two different reagents are used for quantitative measurements of Urine Albumin, Urine Creatinine and Urine Albumin-to-Creatinine Ratio. They are freeze dried and preloaded into the ACT by Zensorium Cartridge and can be stored at room temperature of 25°C for up to 12 months.
In order to detect ACR, two different reagents are used for Albumin and Creatinine separately. Both reagents are freeze dried and preloaded into the ACT by Zensorium Cartridge.
Without the need for refrigeration, Dry Reagent technology allows for lower logistical and operational cost, thus making them highly accessible for decentralized prognosis and monitoring of CKD, making the process of patient care much faster and more efficient.